US7955612B1 - Intraluminal device, coating for such device, and method for preparing said device - Google Patents
Intraluminal device, coating for such device, and method for preparing said device Download PDFInfo
- Publication number
- US7955612B1 US7955612B1 US10/089,460 US8946000A US7955612B1 US 7955612 B1 US7955612 B1 US 7955612B1 US 8946000 A US8946000 A US 8946000A US 7955612 B1 US7955612 B1 US 7955612B1
- Authority
- US
- United States
- Prior art keywords
- coating
- intraluminal device
- laminin
- collagen
- intraluminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 48
- 239000011248 coating agent Substances 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 102000004266 Collagen Type IV Human genes 0.000 claims abstract description 15
- 108010042086 Collagen Type IV Proteins 0.000 claims abstract description 15
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 15
- 238000002513 implantation Methods 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 5
- 238000007598 dipping method Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108010008217 nidogen Proteins 0.000 claims description 14
- 239000003102 growth factor Substances 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 11
- 102100037369 Nidogen-1 Human genes 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- 108010031318 Vitronectin Proteins 0.000 claims description 6
- 102100035140 Vitronectin Human genes 0.000 claims description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 description 15
- 108010085895 Laminin Proteins 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000001732 thrombotic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 229910052715 tantalum Inorganic materials 0.000 description 3
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 3
- 230000008467 tissue growth Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940107685 reopro Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000006492 vascular dysfunction Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000007995 vascular wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/062—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
Definitions
- the present invention relates to an intraluminal device, suitable for implantation in a body, which intraluminal device is provided with a coating.
- Intraluminal devices of the above mentioned type are generally known and applied. Such devices are for example applied in the treatment of blood vessel blockage in which the blocked blood vessel first is dilated, followed by placing a vascular prosthesis, in particular a stent, in the blood vessel in order to keep the vessel in the dilated state.
- This treatment does, however, give rise to several problems with regard to the vascular healing, as the natural healing process after such an operation is not regulated and as a consequence thereof undesirable local thrombosis can take place.
- the intraluminal device interacts with the vessel wall surface and the bloodstream.
- the endothelialization of the intraluminal device is generally complete within two to three months after implantation. During this period the patient is at risk of thrombotic occlusion, undesired tissue growth, inflammation and vascular dysfunction.
- Thrombosis can passively be prevented by creating an inert surface which improves the surface characteristics that influence thrombosis. Such characteristics comprise, for example, charge, wettability and topography.
- Thrombosis can also be prevented by binding one or more active components which inhibit thrombosis to the stent surface in order to actively prevent thrombosis.
- active components are prostaglandins, heparins, other thrombin inhibitors, or enzymes such as adenosine phosphatase.
- thrombosis can be controlled by mimicking at the stent surface an already completed thrombotic response. This can be achieved by coating the stent surface with fibrin, thereby creating a controlled thrombus in vitro, as polymerized and stabilised fibrin is no longer thrombogenetic.
- Thrombus formation can also be limited by disguising the stent surface with plasma proteins such as albumin, gamma globulins or phospholipids, which causes the skipping of certain phases in the proteinaceous—thrombotic and cellular—response.
- plasma proteins such as albumin, gamma globulins or phospholipids, which causes the skipping of certain phases in the proteinaceous—thrombotic and cellular—response.
- the above mentioned coatings have an anti-proliferative effect; the growth velocity is inhibited in order to prevent thrombosis or restenosis.
- a coating consisting of an extract of an extracellular biologically active basement membrane composition, derived for instance from the Engelbreth-Holm-Swarm tumor has been described in U.S. Pat. No. 4,829,000. However, it appears that this membrane is not suitable as a stent coating because it forms a thick shell on the stent surface.
- A. Schneider et al, J. Vase. Surgery 15, 649 (1992) describe the application of a coating consisting of fibronectin whereupon bovine corneal endothelial cells grow. The cells were said to produce an extracellular matrix, and removed after 14 days. Thus coated polymer material was seeded with bovine aortic endothelial cells.
- this coating has a proliferative effect, viz. a large growth velocity of the cells but a big chance on thrombosis too.
- this procedure is complicated and may suffer from bio-contamination.
- the present invention aims to provide for an intraluminal device that after implantation in a body adds to an improvement of the process of vascular healing and prevents the formation of thrombosis, excessive tissue growth, inflammation and vascular dysfunction.
- an intraluminal device comprising:
- a suitable substrate is provided on which endothelial cells can adhere.
- the endothelial cells create their own matrix upon which to grow and remain attached.
- providing a coating suitable for endothelial cell growth can shorten the period during which a patient is at risk of thrombotic occlusion.
- Laminin can contribute to the binding properties of the coating to, for example DNA and RNA in gene therapy.
- type IV collagen adds to an improved attachment of the coating on the intraluminal device as well as a better attachment of the endothelial cells on the coated surface of the intraluminal device.
- the heparan sulfate is an important component as it has an effective anti-thrombogenic effect.
- the coating according to the present invention provides a surface which is higher up in the natural healing cycle.
- the coating provides a fertile rich environment for endothelial cells and regulated thrombus formation.
- the coating according to the present invention has a proliferative effect. As a result of the proliferative effect, the vascular wound healing is stimulated thereby decreasing the period during which thrombosis can occur and excessive tissue growth.
- the coating comprises entactin and nidogen.
- Said compounds add to the structural integrity of the coating and also improve the attachment of the—endothelial—cells to the intraluminal device coating.
- the coating furthermore comprises a growth factor.
- the growth factor is chosen from the group consisting of bFGF, IGF, TGF- ⁇ and VEGF.
- bFGF basic fibroblast growth factor
- IGF insulin like growth factor
- TGF- ⁇ transforming growth factor- ⁇
- VEGF vascular endothelial growth factor
- the coating advantageously comprises an antibiotic.
- the antibiotic should be a broad spectrum antibiotic, such as gentamycine.
- the coating of the intraluminal device according to the present invention comprises vitronectin.
- Vitronectin offers a good basis for cell attachment; moreover it binds abciximab, GP 2b/3b inhibitor (ReoPro®) which is a compound with a known anti-thrombotic effect.
- ReoPro® GP 2b/3b inhibitor
- the coating comprises:
- the intraluminal device comprises a vascular prosthesis such as a stent or a graft.
- a vascular prosthesis such as a stent or a graft.
- the stent as well as the graft can be prepared from different materials known to the person skilled in the art.
- the coated intraluminal device according to the present invention can furthermore be used as a basis for therapies such as, for example, drug delivery and gene therapy.
- Drugs can be bound to the coating such that the release thereof is controlled.
- the presence of laminin in the coating improves the bonds which are desired and required in gene therapy. It is also possible to provide for one or more radioactive molecules in the coating in order to inhibit cell growth, if desired.
- the present invention also relates to a coating suitable for application to an intraluminal device according to the present invention.
- the present invention also relates to a method for preparing an intraluminal device according to the above invention, comprising the steps of:
- the method as such is very simple and easy to perform and moreover is not time-consuming.
- the drying step can take place with or without heated or forced air drying.
- compositions to be prepared furthermore comprise one or more of the group consisting of a growth factor such as bFGF, IGF, TGF- ⁇ and VEGF, an antibiotic and vitronectin.
- a growth factor such as bFGF, IGF, TGF- ⁇ and VEGF, an antibiotic and vitronectin.
- a method for preparing a intraluminal device comprising the steps of:
- the stents were percutaneously implanted using sterile techniques in coronary arteries of farm-bred Yorkshire swines (ca. 30 kg) in such a way that one of each stent was placed per animal.
- One of the two matrigel coated stents showed thrombotic occlusion within one week.
- the stent coated according to the present invention in the same animal was in a condition at autopsy.
- Mean neointimal thickness at one week was 24 ⁇ m (range 20-44 ⁇ m) in the matrigel coated stent and 14 ⁇ m (range 10-24 ⁇ m) in the stent coated according to the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Adornments (AREA)
- Polishing Bodies And Polishing Tools (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Pens And Brushes (AREA)
Abstract
Disclosed is an intraluminal device, suitable for implantation in a body. The intraluminal device is provided with a coating which comprises: 50-97% heparan sulfate; 1-20% laminin; 0.2-15% type IV collagen. Furthermore a coating is disclosed, which coating is suitable for the above mentioned device, as well as a method for preparing such device, comprising the steps of: providing a intraluminal device for implantation in a body; preparing a composition, comprising, in about 50 mg/ml solvent: 50-97% heparan sulfate; 1-20% laminin; 0.2-15% type IV collagen; the solvent being a suitable buffer or water; dipping the intraluminal device in the composition; and drying the dipped intraluminal device.
Description
This is a National Stage of PCT/EP00/09658 filed Oct. 2, 2000 that claims priority of European Application 99203203.7 filed Sep. 30, 1999.
The present invention relates to an intraluminal device, suitable for implantation in a body, which intraluminal device is provided with a coating.
Intraluminal devices of the above mentioned type are generally known and applied. Such devices are for example applied in the treatment of blood vessel blockage in which the blocked blood vessel first is dilated, followed by placing a vascular prosthesis, in particular a stent, in the blood vessel in order to keep the vessel in the dilated state. This treatment does, however, give rise to several problems with regard to the vascular healing, as the natural healing process after such an operation is not regulated and as a consequence thereof undesirable local thrombosis can take place.
After the above implantation, the intraluminal device interacts with the vessel wall surface and the bloodstream. In a clinical setting the endothelialization of the intraluminal device is generally complete within two to three months after implantation. During this period the patient is at risk of thrombotic occlusion, undesired tissue growth, inflammation and vascular dysfunction.
There are several techniques available for controlling the above undesired effects of intraluminal devices, such as for example vascular stents. Thrombosis can passively be prevented by creating an inert surface which improves the surface characteristics that influence thrombosis. Such characteristics comprise, for example, charge, wettability and topography.
Thrombosis can also be prevented by binding one or more active components which inhibit thrombosis to the stent surface in order to actively prevent thrombosis. Examples of such components are prostaglandins, heparins, other thrombin inhibitors, or enzymes such as adenosine phosphatase.
Furthermore, thrombosis can be controlled by mimicking at the stent surface an already completed thrombotic response. This can be achieved by coating the stent surface with fibrin, thereby creating a controlled thrombus in vitro, as polymerized and stabilised fibrin is no longer thrombogenetic.
Thrombus formation can also be limited by disguising the stent surface with plasma proteins such as albumin, gamma globulins or phospholipids, which causes the skipping of certain phases in the proteinaceous—thrombotic and cellular—response.
The above mentioned coatings have an anti-proliferative effect; the growth velocity is inhibited in order to prevent thrombosis or restenosis.
A coating consisting of an extract of an extracellular biologically active basement membrane composition, derived for instance from the Engelbreth-Holm-Swarm tumor has been described in U.S. Pat. No. 4,829,000. However, it appears that this membrane is not suitable as a stent coating because it forms a thick shell on the stent surface. A. Schneider et al, J. Vase. Surgery 15, 649 (1992) describe the application of a coating consisting of fibronectin whereupon bovine corneal endothelial cells grow. The cells were said to produce an extracellular matrix, and removed after 14 days. Thus coated polymer material was seeded with bovine aortic endothelial cells.
However, also this coating has a proliferative effect, viz. a large growth velocity of the cells but a big chance on thrombosis too. Moreover, this procedure is complicated and may suffer from bio-contamination.
The present invention aims to provide for an intraluminal device that after implantation in a body adds to an improvement of the process of vascular healing and prevents the formation of thrombosis, excessive tissue growth, inflammation and vascular dysfunction.
In order to achieve this, the present invention is directed to an intraluminal device comprising:
-
- 50-97% heparan sulfate;
- 1-20% laminin;
- 0.2-15% type IV collagen.
By providing an intraluminal device with a coating of the above specified composition a suitable substrate is provided on which endothelial cells can adhere. During the growth the endothelial cells create their own matrix upon which to grow and remain attached. Given that the normal endothelium is non-thrombogenic, providing a coating suitable for endothelial cell growth can shorten the period during which a patient is at risk of thrombotic occlusion.
All of the above components are also naturally present in the basement membrane of the blood vessel wall and are suitable for endothelial cell adhesion, growth and differentiation. Laminin can contribute to the binding properties of the coating to, for example DNA and RNA in gene therapy. Furthermore, type IV collagen adds to an improved attachment of the coating on the intraluminal device as well as a better attachment of the endothelial cells on the coated surface of the intraluminal device. Finally, the heparan sulfate is an important component as it has an effective anti-thrombogenic effect.
The coating according to the present invention provides a surface which is higher up in the natural healing cycle. The coating provides a fertile rich environment for endothelial cells and regulated thrombus formation. Thus, contrary to the coatings according to the prior art, the coating according to the present invention has a proliferative effect. As a result of the proliferative effect, the vascular wound healing is stimulated thereby decreasing the period during which thrombosis can occur and excessive tissue growth.
In a particular embodiment the coating comprises:
-
- 75-95% heparan sulfate;
- 3-10% laminin;
- 0.5-10% type IV collagen.
In a further preferred embodiment the coating comprises entactin and nidogen.
Said compounds add to the structural integrity of the coating and also improve the attachment of the—endothelial—cells to the intraluminal device coating.
In another advantageous embodiment the coating furthermore comprises a growth factor.
Growth factors in general stimulate the growth of—for example, endothelial—cells and therefore enhance the proliferative effect.
Preferably, the growth factor is chosen from the group consisting of bFGF, IGF, TGF-β and VEGF.
The different growth factors bFGF (basic fibroblast growth factor), IGF (insulin like growth factor), TGF-β (transforming growth factor-β), and VEGF (vascular endothelial growth factor) all add to the growth of specific components.
In order to prevent any risk of infection, the coating advantageously comprises an antibiotic.
In order to have an optimal effect the antibiotic should be a broad spectrum antibiotic, such as gentamycine.
In a preferred embodiment the coating of the intraluminal device according to the present invention comprises vitronectin.
Vitronectin offers a good basis for cell attachment; moreover it binds abciximab, GP 2b/3b inhibitor (ReoPro®) which is a compound with a known anti-thrombotic effect. By incorporating vitronectin in the intraluminal device coating and administering to a patient ReoPro® or other drugs that bind to vitronectin, thrombosis is even further prevented.
In a particular preferred embodiment of the intraluminal device according to the present invention, the coating comprises:
-
- 85-95% heparan sulfate;
- 5-6% laminin;
- 3-4% type IV collagen;
- 0.5-1.5% entactin and nidogen;
- 0.001-1% growth factors;
- 0.001-1% antibiotic.
In a preferred embodiment the intraluminal device comprises a vascular prosthesis such as a stent or a graft. The stent as well as the graft can be prepared from different materials known to the person skilled in the art.
The coated intraluminal device according to the present invention can furthermore be used as a basis for therapies such as, for example, drug delivery and gene therapy. Drugs can be bound to the coating such that the release thereof is controlled. As mentioned in the above, the presence of laminin in the coating improves the bonds which are desired and required in gene therapy. It is also possible to provide for one or more radioactive molecules in the coating in order to inhibit cell growth, if desired.
The present invention also relates to a coating suitable for application to an intraluminal device according to the present invention.
It will be clear that such coating may also be used on other substrates which can be implanted in a body.
The present invention also relates to a method for preparing an intraluminal device according to the above invention, comprising the steps of:
-
- providing an intraluminal device such as a wire of stainless steel, tantalum or polytetrafluoroethylene (PTFE) for implantation in a body;
- preparing a composition, comprising, in about 50 mg/ml solvent:
- 50-97% heparan sulfate;
- 1-20% laminin;
- 0.2-15% type IV collagen;
- the solvent being a suitable buffer or water;
- dipping the intraluminal device in the composition; and
- drying the dipped intraluminal device.
The method as such is very simple and easy to perform and moreover is not time-consuming. The drying step can take place with or without heated or forced air drying.
Preferred embodiments of the method according to the present invention are those wherein the compositions to be prepared furthermore comprise one or more of the group consisting of a growth factor such as bFGF, IGF, TGF-β and VEGF, an antibiotic and vitronectin.
Preferably, a method for preparing a intraluminal device according to the above particular preferred embodiment, comprising the steps of:
-
- providing an intraluminal device such as a wire of stainless steel, tantalum or polytetrafluoroethylene (PTFE) for implantation in a body;
- preparing a composition, comprising, in about 50 mg/ml solvent:
- 85-95% heparan sulfate;
- 5-6% laminin;
- 3-4% type IV collagen;
- 0.5-1.5% entactin and nidogen;
- 0.001-1% growth factors;
- 0.001-1% antibiotic;
- the solvent being a suitable buffer or water;
- dipping the intraluminal device in the composition; and
- drying the dipped intraluminal device.
The present invention will be illustrated by the following, in no way the invention limiting, example.
Helical coil, tantalum coronary stents were coated with the matrigel (n=2) as described in U.S. Pat. No. 4,829,000 or with a coating according to the present invention (n=2).
The stents were percutaneously implanted using sterile techniques in coronary arteries of farm-bred Yorkshire swines (ca. 30 kg) in such a way that one of each stent was placed per animal.
One of the two matrigel coated stents showed thrombotic occlusion within one week. The stent coated according to the present invention in the same animal was in a condition at autopsy. Mean neointimal thickness at one week was 24 μm (range 20-44 μm) in the matrigel coated stent and 14 μm (range 10-24 μm) in the stent coated according to the present invention.
In vitro platelet aggregation was measured in fresh, heparinized blood by measuring the impedance between the two electrodes. For this study the electrodes itself were coated with either matrigel or with the coating according to the present invention. Matrigel coating caused a decrease in impedance of 40% compared to a bare electrode. The coating with a composition according to the present invention caused a decrease of 60%. This implies a reduction of platelet aggregation in whole blood of the coating according to the present invention.
Claims (17)
1. An intraluminal device, suitable for implantation in a body, which device is provided with a coating, wherein the coating comprises:
50-97% heparan sulfate;
1-20% laminin; and
0.2-15% type IV collagen.
2. The intraluminal device according to claim 1 , wherein the coating comprises:
75-95% heparan sulfate;
3-10% laminin; and
0.5-10% type IV collagen.
3. The intraluminal device according to claim 1 , wherein the coating further comprises a growth factor.
4. The intraluminal device according to claim 3 , wherein the growth factor is selected from the group consisting of bFGF, IGF, TGF-β and VEGF.
5. An intraluminal device, suitable for implantation in a body, the device being provided with a coating that comprises:
50-97% heparan sulfate;
1-20% laminin;
0.2-15% type IV collagen; and
an antibiotic.
6. An intraluminal device, suitable for implantation in a body, the device being provided with a coating that comprises:
50-97% heparan sulfate;
1-20% laminin;
0.2-15% type IV collagen; and
an antibiotic comprising gentamycine.
7. The intraluminal device according to claim 1 , wherein the coating further comprises vitronectine.
8. The intraluminal device according to claim 1 , wherein the coating comprises:
85-95% heparan sulfate;
5-6% laminin;
3-4% type IV collagen;
0.5-1.5% entactin and nidogen;
0.001-1% growth factors; and
0.001-1% antibiotic.
9. The intraluminal device according to claim 1 , wherein the intraluminal device is a prosthesis that comprises a stent or a graft.
10. A coating suitable for the intraluminal device according to claim 1 .
11. A method for preparing an intraluminal device, comprising the steps of:
providing an intraluminal device for implantation in a body;
preparing a composition, comprising, in about 50 mg/ml solvent:
50-97% heparan sulfate;
1-20% laminin;
0.2-15% type IV collagen; and
the solvent being a suitable buffer or water;
dipping the intraluminal device in the composition; and
drying the dipped intraluminal device.
12. The method according to claim 11 , wherein the composition further comprises entactin and nidogen.
13. The method according to claim 11 , wherein the composition further comprises a growth factor, selected from the group consisting of bFGF, IGF, TGF-β and VEGF.
14. The method according to claim 11 , wherein the composition further comprises an antibiotic.
15. The method according to claim 11 , wherein the composition further comprises vitronectin.
16. The method according to claim 11 , wherein the composition comprises:
85-95% heparan sulfate;
5-6% laminin;
3-4% type IV collagen;
0.5-1.5% entactin and nidogen;
0.001-1% growth factors; and
0.001-1% antibiotic.
17. The intraluminal device according to claim 1 , wherein the coating further comprises entactin and nidogen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99203203A EP1088564A1 (en) | 1999-09-30 | 1999-09-30 | Intraluminal device, coating for such device, as well as a method for preparing the intraluminal device |
| EP99203203 | 1999-09-30 | ||
| PCT/EP2000/009658 WO2001023016A1 (en) | 1999-09-30 | 2000-10-02 | Intraluminal device, coating for such device, and method for preparing said device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US7955612B1 true US7955612B1 (en) | 2011-06-07 |
Family
ID=8240698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/089,460 Expired - Fee Related US7955612B1 (en) | 1999-09-30 | 2000-10-02 | Intraluminal device, coating for such device, and method for preparing said device |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7955612B1 (en) |
| EP (2) | EP1088564A1 (en) |
| AT (1) | ATE240130T1 (en) |
| AU (1) | AU7912200A (en) |
| DE (1) | DE60002744T2 (en) |
| ES (1) | ES2199182T3 (en) |
| WO (1) | WO2001023016A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140262879A1 (en) * | 2013-03-14 | 2014-09-18 | Cell and Molecular Tissue Engineering, LLC | Cannulas, Collars for Implantable Devices, and Corresponding Systems and Methods |
| CN115006608A (en) * | 2022-01-25 | 2022-09-06 | 河南省人民医院 | Cerebrovascular coated stent and preparation method thereof |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015147A1 (en) | 1998-09-10 | 2000-03-23 | Percardia, Inc. | Transmycardial shunt and its attachment mechanism, for left ventricular revascularization |
| US6641610B2 (en) | 1998-09-10 | 2003-11-04 | Percardia, Inc. | Valve designs for left ventricular conduits |
| US6290728B1 (en) | 1998-09-10 | 2001-09-18 | Percardia, Inc. | Designs for left ventricular conduit |
| US6409697B2 (en) | 1999-05-04 | 2002-06-25 | Heartstent Corporation | Transmyocardial implant with forward flow bias |
| US6638237B1 (en) | 1999-08-04 | 2003-10-28 | Percardia, Inc. | Left ventricular conduits and methods for delivery |
| US7033372B1 (en) | 1999-08-04 | 2006-04-25 | Percardia, Inc. | Corkscrew reinforced left ventricle to coronary artery channel |
| US6854467B2 (en) | 2000-05-04 | 2005-02-15 | Percardia, Inc. | Methods and devices for delivering a ventricular stent |
| US6976990B2 (en) | 2001-01-25 | 2005-12-20 | Percardia, Inc. | Intravascular ventriculocoronary bypass via a septal passageway |
| US6632470B2 (en) | 2001-01-31 | 2003-10-14 | Percardia | Methods for surface modification |
| US6949118B2 (en) | 2002-01-16 | 2005-09-27 | Percardia, Inc. | Encased implant and methods |
| US7008397B2 (en) | 2002-02-13 | 2006-03-07 | Percardia, Inc. | Cardiac implant and methods |
| US7326219B2 (en) | 2002-09-09 | 2008-02-05 | Wilk Patent Development | Device for placing transmyocardial implant |
| US20040236416A1 (en) * | 2003-05-20 | 2004-11-25 | Robert Falotico | Increased biocompatibility of implantable medical devices |
| WO2005099785A1 (en) | 2004-04-15 | 2005-10-27 | Nexilis Ag | Osteogenic composite matrix, method for the production thereof and implant and scaffold for tissue engineering provided with a coating formed by said osteogenic composite matrix |
| JP2008507341A (en) | 2004-07-21 | 2008-03-13 | メドトロニック，インコーポレイティド | Medical device and method for reducing localized fibrosis |
| CN101160144A (en) * | 2005-02-23 | 2008-04-09 | 苏尔莫迪克斯公司 | Implantable medical articles with laminin coatings and methods of use |
| US7591841B2 (en) | 2005-12-16 | 2009-09-22 | Advanced Cardiovascular Systems, Inc. | Implantable devices for accelerated healing |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61128974A (en) | 1984-11-27 | 1986-06-17 | 株式会社アドバンス | Artificial base membrane and its production |
| US4963146A (en) | 1989-04-20 | 1990-10-16 | Colla-Tec Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration |
| WO1995031944A1 (en) | 1994-05-20 | 1995-11-30 | Vec Tec, Inc. | Methods rendering grafts nonthrombogenic and substantially nonimmunogenic |
| WO1999001167A1 (en) | 1997-07-01 | 1999-01-14 | Minnesota Mining And Manufacturing Company | Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine |
| EP0945145A1 (en) | 1996-11-20 | 1999-09-29 | Tapic International Co., Ltd. | Artificial neural canal |
-
1999
- 1999-09-30 EP EP99203203A patent/EP1088564A1/en not_active Withdrawn
-
2000
- 2000-10-02 DE DE60002744T patent/DE60002744T2/en not_active Expired - Lifetime
- 2000-10-02 EP EP00969388A patent/EP1221989B1/en not_active Expired - Lifetime
- 2000-10-02 US US10/089,460 patent/US7955612B1/en not_active Expired - Fee Related
- 2000-10-02 WO PCT/EP2000/009658 patent/WO2001023016A1/en not_active Ceased
- 2000-10-02 ES ES00969388T patent/ES2199182T3/en not_active Expired - Lifetime
- 2000-10-02 AU AU79122/00A patent/AU7912200A/en not_active Abandoned
- 2000-10-02 AT AT00969388T patent/ATE240130T1/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61128974A (en) | 1984-11-27 | 1986-06-17 | 株式会社アドバンス | Artificial base membrane and its production |
| US4963146A (en) | 1989-04-20 | 1990-10-16 | Colla-Tec Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration |
| WO1995031944A1 (en) | 1994-05-20 | 1995-11-30 | Vec Tec, Inc. | Methods rendering grafts nonthrombogenic and substantially nonimmunogenic |
| EP0945145A1 (en) | 1996-11-20 | 1999-09-29 | Tapic International Co., Ltd. | Artificial neural canal |
| WO1999001167A1 (en) | 1997-07-01 | 1999-01-14 | Minnesota Mining And Manufacturing Company | Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine |
Non-Patent Citations (3)
| Title |
|---|
| A Schneider et al. "An Improved Method for Endothelial Cell Seeding on Polytetrafluoroethylene Small Caliber Vascular Grafts." Journal of Vascular Surgery. (Apr. 1992) 15 (4) 649-56. XP000884442 the whole document. |
| Aviva Schneider et al., "An Improved Method for Endothelial Cell Seeding on Polytetrafluoroethylene Small Caliber Vascular Grafts," Journal of Vascular Surgery, vol. 15, 1992, pp. 649-656. |
| Cell Adhesion Proteins, Encyclopedia of Molecular Medicine, p. 1-12, 2002. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140262879A1 (en) * | 2013-03-14 | 2014-09-18 | Cell and Molecular Tissue Engineering, LLC | Cannulas, Collars for Implantable Devices, and Corresponding Systems and Methods |
| CN115006608A (en) * | 2022-01-25 | 2022-09-06 | 河南省人民医院 | Cerebrovascular coated stent and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1221989A1 (en) | 2002-07-17 |
| ATE240130T1 (en) | 2003-05-15 |
| DE60002744D1 (en) | 2003-06-18 |
| AU7912200A (en) | 2001-04-30 |
| EP1088564A1 (en) | 2001-04-04 |
| WO2001023016A1 (en) | 2001-04-05 |
| ES2199182T3 (en) | 2004-02-16 |
| DE60002744T2 (en) | 2004-04-15 |
| EP1221989B1 (en) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7955612B1 (en) | Intraluminal device, coating for such device, and method for preparing said device | |
| US6503954B1 (en) | Biocompatible carrier containing actinomycin D and a method of forming the same | |
| US7544673B2 (en) | Coating compositions for bioactive agents | |
| US5660873A (en) | Coating intraluminal stents | |
| EP1979013B1 (en) | Coated medical devices and methods of making the same | |
| Qi et al. | Surface modification of cardiovascular materials and implants | |
| CN100455275C (en) | Medical device coated with a coating that promotes endothelial cell adhesion and differentiation | |
| EP0879595B1 (en) | Drug-releasing coatings for medical devices | |
| US8790920B2 (en) | Decellularized bone marrow extracellular matrix | |
| US20020119178A1 (en) | Drug eluting device for treating vascular diseases | |
| US20020138048A1 (en) | Medical device for delivering a therapeutic agent and method of preparation | |
| CN101631514A (en) | Multi-drug eluting coronary stent for percutaneous coronary intervention | |
| JP6404238B2 (en) | Medical device having a biocompatible coating | |
| CN106620897B (en) | An anti-restenosis intraluminal stent material | |
| Sharma | Biomaterials: Role of surface modifications | |
| EP3190969B1 (en) | Method for the manufacturing of coated implants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ORBUS MEDICAL TECHNOLOGIES, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN DER GIESSEN, WILLEM JOHAN;VAN BEUSEKOM, HELENA M M;SIGNING DATES FROM 20020325 TO 20020326;REEL/FRAME:012936/0404 |
|
| AS | Assignment |
Owner name: ORBUS MEDICAL TECHNOLOGIES, INC., FLORIDA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND ASSIGNOR'S NAME PREVIOULSY RECORDED ON REEL 12936, FRAME 404. ASSIGNOR HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST;ASSIGNORS:VAN DER GIESSEN, WILLEM JOHAN;VAN BEUSEKOM, HELENA MARGARETHA MARIA;SIGNING DATES FROM 20020325 TO 20020326;REEL/FRAME:013239/0312 |
|
| AS | Assignment |
Owner name: ORBUSNEICH MEDICAL, INC., DELAWARE Free format text: CHANGE OF NAME;ASSIGNOR:ORBUS MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:018688/0747 Effective date: 20060814 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
| AS | Assignment |
Owner name: ORBUSNEICH MEDICAL PTE. LTD., SINGAPORE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ORBUSNEICH MEDICAL, INC.;REEL/FRAME:050785/0550 Effective date: 20181101 |
|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| AS | Assignment |
Owner name: ORBUSNEICH MEDICAL PTE. LTD., SINGAPORE Free format text: CHANGE OF ADDRESS;ASSIGNOR:ORBUSNEICH MEDICAL PTE. LTD.;REEL/FRAME:059171/0022 Effective date: 20210421 |
|
| AS | Assignment |
Owner name: ORBUSNEICH MEDICAL PTE. LTD., SINGAPORE Free format text: CHANGE OF ADDRESS;ASSIGNOR:ORBUSNEICH MEDICAL PTE. LTD.;REEL/FRAME:060386/0417 Effective date: 20220615 |
|
| FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20230607 |